Project Grant R01CA297604
- The National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded a $1,770,000 Project Grant to Raiz Diagnostics, Inc. to advance the clinical deployment and regulatory readiness of its LymphomaDx diagnostic assay. The grant aims to generate CLPA expression data from 2,500 clinically suspected lymphoma cases to train and validate a diagnostic classifier that can achieve 95% sensitivity/specificity for lymphoma detection and 90% top-1...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- This Project Grant award of $306,798 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop an artificial intelligence-based system to accurately identify malignant lymph nodes. The key objectives are to: Create a lymph node segmentation model to enable extraction of radiomic features critical for malignancy classification. Develop both cloud-based and standalone desktop deployment options for the classification model to...
- The National Cancer Institute awarded a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Feinstein Institutes For Medical Research in New York. The grant supports research to understand the communication between cancer cells and cancer-associated fibroblasts in chronic lymphocytic leukemia (CLL). The project aims to identify potential therapeutic targets within the CLL tumor microenvironment in order to improve treatment outcomes. Specifically, the research...
- The National Cancer Institute (NCI) awarded a $591,468 Project Grant on August 6, 2025 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Research Foundation for the State University of New York (SUNY Oswego). The funding supports research to develop explainable machine learning models based on deep cancer pathophysiology to improve cancer diagnosis, risk stratification, and therapeutic recommendations. The project aims to address key gaps in integrating heterogeneous...
- This Project Grant award, titled "Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining its Regulation and Cellular Interactions", is funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) for $241,884.00. The award will be carried out by the Dana-Farber Cancer Institute, Inc. (DFCI) from September 3, 2025 through August 31, 2030. The project aims to characterize the role of the non-classical HLA-E molecule in immune evasion by diffuse large...
- The Project Grant award of $806,693.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports a research project at New York University (NYU) titled "LYMPHATIC CONTROL OF GERMINAL CENTERS." The project aims to investigate the role of the lymphatic vasculature in regulating immune responses, with a focus on understanding how lymphangiogenesis (growth of new lymphatic vessels) shapes...
- This federal Project Grant award of $418,176 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and validation of a novel approach called "Programmable Nucleic Acid Cytometry" at the Sloan-Kettering Institute for Cancer Research. The project aims to advance this innovative method for profiling rare cell populations from tumors and tissues, which offers advantages over traditional antibody-based cell isolation techniques. The work will...
- This National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) Project Grant award of $683,089 to the Sloan-Kettering Institute for Cancer Research supports the development of an improved, interpretable deep learning algorithm called DeepLIIF for more reproducible and accurate PD-L1 immunohistochemistry (IHC) biomarker quantification. The goal is to leverage virtual multiplex immunofluorescence (MPIF) restaining and large, diverse datasets across lung and bladder cancers to...
- This $204,027 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting the Weill Medical College of Cornell University in expanding single-cell and spatial technologies to link clonal genotypes with phenotypes during cancer evolution. The grant aims to develop advanced single-cell methods that can capture multiple data modalities, including genotypes, transcriptomes, methylomes, and protein expression, to better understand how somatic...
This federal Project Grant award of $714,110.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research by New York University School of Medicine to translate insights in follicular lymphoma for improved diagnosis and classification. The research aims to identify reliable predictive biomarkers to guide frontline risk stratification and treatment for high-risk follicular lymphoma patients, who face a poor prognosis due to early disease progression or histologic transformation. This 5-year research project, beginning September 1, 2025, will leverage the institution's expertise in cancer genomics and tumor microenvironment analysis to develop advanced diagnostic tools and risk assessment models to improve outcomes for this challenging lymphoma subtype.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $714.1k | 8/28/25 |